6.6(top 5%)
impact factor
279(top 50%)
papers
21.7K(top 10%)
citations
56(top 10%)
h-index
7.0(top 5%)
extended IF
375
all documents
23.1K
doc citations
144(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)Kidney International Supplements20171,214
2Chapter 1: Definition and classification of CKDKidney International Supplements2013861
3Section 2: AKI DefinitionKidney International Supplements2012677
4Epidemiology of chronic kidney disease: an update 2022Kidney International Supplements2022596
5Risk factors for chronic kidney disease: an updateKidney International Supplements2013389
6Summary of Recommendation StatementsKidney International Supplements2013370
7United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal diseaseKidney International Supplements2015335
8Summary of Recommendation StatementsKidney International Supplements2012254
9Wnt/β-catenin signaling and kidney fibrosisKidney International Supplements2014221
10Diagnosis of diabetic kidney disease: state of the art and future perspectiveKidney International Supplements2018202
11Overview of the cellular and molecular basis of kidney fibrosisKidney International Supplements2014193
12Macrophages promote renal fibrosis through direct and indirect mechanismsKidney International Supplements2014177
13Chapter 2: Definition, identification, and prediction of CKD progressionKidney International Supplements2013156
14Reducing major risk factors for chronic kidney diseaseKidney International Supplements2017155
15KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney DiseaseKidney International Supplements2018141
16Global nephrology workforce: gaps and opportunities toward a sustainable kidney care systemKidney International Supplements2018123
17Chapter 10: Immunoglobulin A nephropathyKidney International Supplements2012122
18Chapter 3: Management of progression and complications of CKDKidney International Supplements2013121
19Current status of end-stage renal disease care in India and PakistanKidney International Supplements2013112
20Complications of chronic kidney disease: current state, knowledge gaps, and strategy for actionKidney International Supplements2017106
21Chapter 7: Idiopathic membranous nephropathyKidney International Supplements2012103
22Obesity, oxidative stress, and fibrosis in chronic kidney diseaseKidney International Supplements2014100
23Biology of stem cells: an overviewKidney International Supplements201194
24Section 5: Dialysis Interventions for Treatment of AKIKidney International Supplements201292
25A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney diseaseKidney International Supplements201385
26China Kidney Disease Network (CK-NET) 2015 Annual Data ReportKidney International Supplements201983
27Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas projectKidney International Supplements201882
28Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosisKidney International Supplements201478
29Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activationKidney International Supplements201177
30Key fibrogenic mediators: old players. Renin–angiotensin systemKidney International Supplements201477
31What is the best way to measure renal fibrosis?: A pathologist’s perspectiveKidney International Supplements201476
32Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney diseaseKidney International Supplements202175
33Work Group MembershipKidney International Supplements201274
34Renal registry in Hong Kong—the first 20 yearsKidney International Supplements201574
35Chapter 3: Steroid-sensitive nephrotic syndrome in childrenKidney International Supplements201270
36Uremic osteoporosisKidney International Supplements201370
37Toll-like receptor activation: from renal inflammation to fibrosisKidney International Supplements201470
38Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis populationKidney International Supplements201570
39China Kidney Disease Network (CK-NET) 2016 Annual Data ReportKidney International Supplements202070
40Training nephrologists from developing countries: does it have a positive impact?Kidney International Supplements201268
41Chapter 1: Diagnosis and evaluation of anemia in CKDKidney International Supplements201268
42Hypoxia and fibrosis in chronic kidney disease: crossing at pericytesKidney International Supplements201467
43Australia and New Zealand Dialysis and Transplant RegistryKidney International Supplements201565
44Chapter 12: Lupus nephritisKidney International Supplements201264
45Chapter 11: Henoch-Schönlein purpura nephritisKidney International Supplements201264
46Cardiovascular and other effects of salt consumptionKidney International Supplements201364
47AOPPs and the progression of kidney diseaseKidney International Supplements201461
48The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agendaKidney International Supplements201157
49Towards prevention of chronic kidney disease in Nigeria: a community-based study in Southeast NigeriaKidney International Supplements201357
50The FOXD1 lineage of kidney perivascular cells and myofibroblasts: functions and responses to injuryKidney International Supplements201457